Transfusion-Transmitted Viruses Study (TTVS)
Open BioLINCC Study See bottom of this webpage for request information
September 3, 2009
Clinical Trial URLs
Primary Publication URLs
Commercial Use Specimen Restrictions No
Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes
Genetic Use Of Specimens Allowed? Yes
Genetic Use Area Of Research Restrictions Yes
Specific Consent Restrictions
Consent for both genetic and non-genetic use of biospecimens is restricted to studies involving transfusion safety.
To establish a repository of specimens collected from prospectively identified cases of non-A, non-B (NANB) hepatitis after blood transfusion. The major intentions were to determine the incidence of that occurrence, identify the characteristics of the donors associated with the event, and have a resource available to compare laboratory donor screening methods during the study and in subsequent years following completion of the study.
From July 1974 through June 1980, the TTVS group prospectively identified cases of NANB hepatitis in a cohort of 1,533 transfused patients hospitalized short-term for various routine operative procedures. The TTVS collection has been used in a variety of studies, such as the evaluation and validation of Hepatitis C Virus (HCV) immunoassays in screening blood donors (1). In addition, specimens have been requested to evaluate poorly characterized hepatotropic viruses, transmissibility of new viruses (hepatitis G, HHV-8) by transfusion, and the dynamics of HBV/HCV viral replication and seroconversion in recipients.
Serum specimens from 5,655 blood donors were collected from 4 participating blood centers distributed across the US. 3,121 patients were consented to participate in a study of viral hepatitis after blood transfusion. The majority of patients were scheduled for elective surgery. Of these subjects, 1,533 subsequently received blood transfusions. Both transfusion recipients and control subjects that did not require transfusion were observed and blood was collected prior to surgery or pre-transfusion and again during visits at 2-3 week intervals during the first 6 months following the transfusion episode and again between 8-10 months.
The collection originally consisted of aliquots of serum acquired at patient observation visits and from the collection agency for every donor to each TTVS recipient. These sera included the pre-transfusion or pre-surgical specimen, all interval blood draws from these patients and the non-transfused control patients, a specimen from the donor at the time of blood collection and in a subpopulation of donors a follow-up specimen from donors implicated in suspected cases of transfusion transmitted hepatitis and a matched set of non-implicated donors.
The TTVS collection provides sera from a large transfusion donor-recipient study in which an untransfused control population with reasonably matched characteristics and of adequate size is available.
- Mosley JW, et al. (1990) Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA 263(1):77-78.
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
|Plasma or Serum|
|Total number of subjects||Average volume (ml) per subject|
|Recipient Visit 1||985||0.22|
|Recipient Visit 2||21||0.25|
|Recipient Visit 3||32||0.26|
|Recipient Visit 4||85||0.24|
|Recipient Visit 5||293||0.25|
|Recipient Visit 6||773||0.26|
|Recipient Visit 7||203||0.25|
|Recipient Visit 8||289||0.25|
|Recipient Visit 9||696||0.26|
|Recipient Visit 10||247||0.24|
|Recipient Visit 11||305||0.24|
|Recipient Visit 12||591||0.24|
|Recipient Visit 13||165||0.23|
|Recipient Visit 14||49||0.24|
|Recipient Visit 15||27||0.22|
|Recipient Visit 16||19||0.21|
|Recipient Visit 17||13||0.21|
|Recipient Visit 18||14||0.19|
|Recipient Visit 19||8||0.18|
|Recipient Visit 20||7||0.19|
|Recipient Visit 21||3||0.20|
|Recipient Visit 22||5||0.17|
|Recipient Visit 24||2||0.15|
|Recipient Visit 25||1||0.05|
Requests for Open BioLINCC Studies are submitted through this website. Click the Request button to begin.
Resources AvailableSpecimens Only
- Plasma or Serum
- More Details
Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.